Novo Nordisk A/S Increased Reported Operating Profit By 8% In The First Six Months Of 2017

Published: Aug 09, 2017

Sales increased by 4% measured in Danish kroner

Sales increased by 4% in Danish kroner and by 3% in local currencies to DKK 57.1 billion.

Sales of Tresiba® increased by 155% to DKK 3.7 billion (149% in local currencies)

Sales of Victoza® increased by 21% to DKK 11.5 billion (18% in local currencies).

Sales of Saxenda® increased by 98% to DKK 1.2 billion (90% in local currencies)

Back to news